Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $30.0909.

Several analysts have recently issued reports on the company. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Truist Financial initiated coverage on shares of Immunome in a report on Monday, December 1st. They issued a “buy” rating and a $36.00 target price on the stock. Lake Street Capital boosted their target price on shares of Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Finally, Evercore ISI lifted their price objective on shares of Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday.

Immunome Stock Down 15.8%

Shares of NASDAQ:IMNM opened at $19.78 on Thursday. Immunome has a 12-month low of $5.15 and a 12-month high of $25.30. The company’s 50 day moving average price is $17.42 and its two-hundred day moving average price is $12.55. The firm has a market cap of $1.81 billion, a PE ratio of -6.71 and a beta of 2.17.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, research analysts expect that Immunome will post -2.21 EPS for the current year.

Hedge Funds Weigh In On Immunome

Institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. boosted its stake in Immunome by 37.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock valued at $50,843,000 after buying an additional 2,054,640 shares in the last quarter. Redmile Group LLC lifted its holdings in shares of Immunome by 11.0% in the first quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock worth $36,081,000 after acquiring an additional 533,161 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Immunome by 8.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company’s stock valued at $57,304,000 after purchasing an additional 368,674 shares in the last quarter. EcoR1 Capital LLC grew its holdings in shares of Immunome by 5.2% during the 1st quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company’s stock valued at $27,454,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Immunome by 6.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock worth $17,305,000 after purchasing an additional 117,523 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.